AbbVie Inc. Annual Report, Year Ended Dec 31, 2013

AbbVie Inc. completed its first full year as an independent, publicly traded company in 2013, reporting a 2% increase in net sales to $18.8 billion. This growth was primarily driven by strong performance from its flagship product, HUMIRA, which accounted for 57% of total sales, and positive contributions from other key products like Synthroid and Creon. The company successfully navigated the loss of exclusivity for its lipid franchise due to generic competition, which negatively impacted revenue by $1.1 billion, but offset this through disciplined cost management and operational efficiencies. AbbVie also maintained a strong balance sheet, generating $6.3 billion in cash flow from operations, enabling it to invest in its robust pipeline and return capital to shareholders through dividends. The company continues to focus on expanding HUMIRA's indications and market reach, alongside advancing over 20 compounds in its development pipeline across critical therapeutic areas, positioning itself for future growth. Key risks for investors revolve around the potential impact of HUMIRA's patent expiration in December 2016 and the ensuing competition from biosimilars. AbbVie's reliance on HUMIRA represents a significant concentration of revenue, making its market exclusivity a critical factor for future performance. The company is also actively managing its R&D pipeline, with substantial investments in areas like immunology, virology, and oncology, but the inherent uncertainties in drug development mean that pipeline success is not guaranteed. Additionally, regulatory changes, pricing pressures, and the competitive landscape for pharmaceuticals remain ongoing challenges.